Aprea Therapeutics Ownership
| APRE Stock | USD 1.06 0.03 2.91% |
Shares in Circulation | First Issued 2018-09-30 | Previous Quarter 6.1 M | Current Value 6.4 M | Avarage Shares Outstanding 2.5 M | Quarterly Volatility 2.1 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aprea Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. Aprea Stock Ownership Analysis
About 21.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.59. Some equities with similar Price to Book (P/B) outperform the market in the long run. Aprea Therapeutics recorded a loss per share of 2.12. The entity had not issued any dividends in recent years. The firm had 1:20 split on the 13th of February 2023. Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. The companys products pipeline also includes ATRN-Backup, an ATR inhibitor ATRN-W1051 to treat anti-tumor activity and ATRN-DDRi. Aprea Therapeutics is traded on NASDAQ Exchange in the United States. For more info on Aprea Therapeutics please contact Christian Schade at 215 948 4119 or go to https://aprea.com.Aprea Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Aprea Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Aprea Therapeutics backward and forwards among themselves. Aprea Therapeutics' institutional investor refers to the entity that pools money to purchase Aprea Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Dimensional Fund Advisors, Inc. | 2025-06-30 | 14.5 K | Hightower Advisors, Llc | 2025-06-30 | 13.9 K | Blackrock Inc | 2025-06-30 | 8.5 K | Bank Of America Corp | 2025-06-30 | 4.9 K | Tower Research Capital Llc | 2025-06-30 | 3 K | Mb, Levis & Associates, Llc | 2025-06-30 | 806 | Group One Trading, Lp | 2025-06-30 | 577 | Fmr Inc | 2025-06-30 | 501 | Advisor Group Holdings, Inc. | 2025-06-30 | 400 | Aigh Capital Management, Llc | 2025-06-30 | 539.3 K | Sio Capital Management, Llc | 2025-06-30 | 279.4 K |
Aprea Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Aprea Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Aprea Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Aprea Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Aprea Therapeutics Outstanding Bonds
Aprea Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Aprea Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Aprea bonds can be classified according to their maturity, which is the date when Aprea Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US03835VAH96 Corp BondUS03835VAH96 | View | |
| Aptiv 435 percent Corp BondUS03835VAG14 | View | |
| APTIV PLC 44 Corp BondUS03835VAF31 | View | |
| APTV 31 01 DEC 51 Corp BondUS03835VAJ52 | View | |
| ATR 36 15 MAR 32 Corp BondUS038336AA11 | View | |
| US03836WAC73 Corp BondUS03836WAC73 | View | |
| US03836WAB90 Corp BondUS03836WAB90 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Aprea Therapeutics is a strong investment it is important to analyze Aprea Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Aprea Therapeutics' future performance. For an informed investment choice regarding Aprea Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aprea Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For information on how to trade Aprea Stock refer to our How to Trade Aprea Stock guide.You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aprea Therapeutics. If investors know Aprea will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aprea Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.12) | Revenue Per Share | Quarterly Revenue Growth (0.99) | Return On Assets | Return On Equity |
The market value of Aprea Therapeutics is measured differently than its book value, which is the value of Aprea that is recorded on the company's balance sheet. Investors also form their own opinion of Aprea Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aprea Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aprea Therapeutics' market value can be influenced by many factors that don't directly affect Aprea Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aprea Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aprea Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aprea Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.